Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models

Despite the availability of several Food and Drug Administration-approved drugs, advanced inoperable colorectal cancer remains incurable. In this study, we focused on the development of combined molecular targeted therapies against colon cancer by testing the efficacy of the combination of the histo...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2009-02, Vol.8 (2), p.342-349
Main Authors: Pitts, Todd M, Morrow, Mark, Kaufman, Sara A, Tentler, John J, Eckhardt, S Gail
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Boronic Acids - pharmacology
Bortezomib
Cell Cycle - drug effects
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
colon cancer
Colonic Neoplasms - pathology
Drug Screening Assays, Antitumor
Drug Synergism
Humans
Hydroxamic Acids - pharmacology
Pyrazines - pharmacology
Signal Transduction - drug effects
vorinostat
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the availability of several Food and Drug Administration-approved drugs, advanced inoperable colorectal cancer remains incurable. In this study, we focused on the development of combined molecular targeted therapies against colon cancer by testing the efficacy of the combination of the histone deacetylase inhibitor vorinostat with the proteasome inhibitor bortezomib to determine if this resulted in synergistic antitumor effects against colorectal cancer. The effects of the histone deacetylase inhibitor vorinostat in combination with the proteasome inhibitor bortezomib on the growth of two colorectal cancer cell lines were assessed with regard to proliferation, cell cycle arrest, and apoptosis. Treatment with the combination of vorinostat and bortezomib resulted in a synergistic decrease in proliferation of both colorectal cancer cell lines compared with treatment with single agents alone. This inhibition was associated with a synergistic increase in apoptosis as measured by caspase-3/7 activity and cleaved poly(ADP-ribose) polymerase. In addition, we observed an increase in the proapoptotic protein BIM and in the number of cells arrested in the G 2 -M phase of the cell cycle. Although p21 levels were significantly increased, short hairpin RNA knockdown of p21 did not lead to changes in proliferation in response to the combination of drugs, indicating that although p21 is a target of these drugs, it is not required to mediate their antiproliferative effects. These data indicate that combination treatment with vorinostat and bortezomib result in synergistic antiproliferative and proapoptotic effects against colon cancer cell lines, providing a rational basis for the clinical use of this combination for the treatment of colorectal cancer. [Mol Cancer Ther 2009;8(2):342–9]
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.MCT-08-0534